Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV: full-pipeline trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV: 2 US clinical trials tracked, none currently recruiting.
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 2 of these trials.
Enrollment posture brief
Registry condition locally-advanced-or-metastatic-non-small-cell-lung-cancer-stage-iiib-iv
OPEN 0 | RECR 0% | LATE 1 | EARLY 1 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
AstraZeneca
NCT01933932
Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.
AstraZeneca
NCT01750281
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- AstraZeneca sponsors the most Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV condition card totals 2 registered trials; most-linked intervention Placebo; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.